Skip to main content
Free research Free research Free assay review with research home and workspace preview
Quick search ChEMBL 36
Assay Detail

CHEMBL5657787

Review assay metadata, readout intent, target linkage, and publication context from the same page.

Binding
Inhibition of recombinant human CHK1 by microfluidic assay
1
Total Activities
1
Compounds Tested
1
Activity Types
2
Assay Parameters

Assay Information

Assay Type Binding
Organism Homo sapiens
Confidence 9 — Direct single protein target
Curated By Autocuration

Target

Serine/threonine-protein kinase Chk1 (CHEMBL4630)
Type SINGLE PROTEIN
Organism Homo sapiens

Publication

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD.
Oncotarget (2016) 7 : 2329 -2342
PubMed 26295308 · DOI

Activity Statistics

Type Count Avg pChEMBL Best pChEMBL
IC50 1 8.85 8.85

Assay Parameters

Parameter Type Value Units Text
EFO_ID EFO_ID - EFO:1001938
EFO_TERM EFO_TERM - b-cell non-hodgkins lymphoma

Compounds Tested

Compound Name Phase Activities Best pChEMBL
CHEMBL4169078 SRA-737 1.0 1 8.85

Activity Data

Compound Name Type Rel. Value Units pChEMBL
CHEMBL4169078 SRA-737 IC50 = 1.4 nM 8.85